QIAGEN delivered Q4 2025 results above its outlook with modest sales growth and stronger adjusted earnings, supported by growth pillars and operating discipline.

QIAGEN delivered solid Q3 2025 results with $533 million in revenue and $0.61 adjusted EPS, surpassing its guidance. Growth was driven by QIAstat-Dx, QuantiFERON, and Sample technologies. The company raised its full-year adjusted EPS target and reaffirmed its revenue growth outlook.

QIAGEN delivered a solid Q2 2025, with revenues rising 7% year-over-year to $534 million and adjusted EPS reaching $0.60. Diagnostic solutions drove double-digit growth, and operating margins improved through efficiency gains.

QIAGEN delivered a strong Q1 2025 performance with $483 million in revenue, 7% constant currency growth, and $0.55 adjusted EPS, surpassing guidance. Operating margins improved and a dividend initiation along with a $500M share repurchase program were announced.